Hallen Ed sold 45,558 shares of Klaviyo, Inc. at $21.52 for −$980k on Nov 5, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed Nov 9, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$980,408.16Shares × reported price
Shares traded
45,558Series A Common Stock
Price per share
$21.52Reported price. Read footnotes for ranges.
% of reported position traded
12.3%This security and ownership context
Holdings after
324,688Indirect · By Hodgkins LLC
Trade date
Nov 5, 2026Sell
Filed
Nov 9, 2026, 4:29 PM ET4-day reporting delay
Accession
0001470831-26-000989Code S · Transaction 395947
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 370,246 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 5, 2026Sell32,663$21.35−$697,355.05Trade 395945
Nov 5, 2026Sell6,504$20.71−$134,697.84Trade 395946
Nov 5, 2026Sell14,057$21.07−$296,180.99Trade 395948
Nov 5, 2026Gift17,885$0.00$0Trade 395949
5 transaction rows in this filing. Joint filers share the same rows.

KVYO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KVYO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −20%1w ago −1.4%1d ago +3.1%
Returns since7d30d90d180d1y

Footnotes in full

F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.99 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Shares are owned directly by Hodgkins Trust for the benefit of the Reporting Person and the Reporting Person's family, and of which the trustee is an independent institution. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.62 to $20.99 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.15 to $22.14 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6: Shares held by Hodgkins LLC, of which the Reporting Person serves as manager. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.97 to $21.14 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8: Represents a bona fide gift of 17,885 shares of stock from Hodgkins LLC, of which Reporting Person serves as manager, to a donor-advised fund pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.